- S&P 500 7,659.44 −1.09%
- Dow Jones 52,002.41 −0.34%
- Nasdaq 26,713.03 +0.08%
- VIX 19.99 +21.45%
- 10-year Treasury 5.09% −0.01
- Dollar index 121.40 −0.14%
- WTI crude $101.91 +1.04%
Biotech calendar: April 2027
Industry-sponsored phase 2 and phase 3 trials with an estimated primary completion in April 2027, from ClinicalTrials.gov.
Trial readouts
182 trials: 66 phase 3 (including phase 2/3) and 116 phase 2. Phase 3 first, then by date. Click a column to sort; type to filter.
| Primary completion | Sponsor | Drug | Condition | Phase | Status | Record |
|---|---|---|---|---|---|---|
| Apr 2027 | AbbVie | Mirvetuximab soravtansine plus Bevacizumab, BevacizumabMirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Pe… | Ovarian Cancer, Peritoneal Cancer and 1 more | Phase 3 | Active not recruiting | NCT05445778 |
| Apr 2027 | Ache Laboratorios Farmaceuticos S.A. | Product DNN.65.21.005, Combodart®Efficacy/ Safety of Product DNN.65.21.005 in Patients With Benign Prostatic Hyperplasia | Prostatic Hyperplasia, Benign | Phase 3 | Not yet recruiting | NCT07270432 |
| Apr 2027 | Beijing Kanghong Biological Medicine Co., Ltd. | KHN939A Phase III Study of KHN939 in Chinese Patients With Moderate-to-Severe Active Thyroid Eye Disease | Thyroid Eye Disease | Phase 3 | Not yet recruiting | NCT07720635 |
| Apr 2027 | Biocad | ANB-002An Open-Label, Comparative Study of the Efficacy, Safety and Pharmacodynamics of Single Dose of ANB-002 in Patients With Hemophilia B | Hemophilia B | Phase 3 | Recruiting | NCT06700096 |
| Apr 2027 | Colgate-Palmolive Company | Silica Free Meridol, Meridol, Colgate Dental ProductClinical Study Examining the Control of Plaque and Gingivitis | Gingivitis | Phase 3 | Not yet recruiting | NCT07842978 |
| Apr 2027 | Coya Therapeutics, Inc. | COYA 302Study of COYA 302 for the Treatment of ALS | Amyotrophic Lateral Sclerosis (ALS) | Phase 2/3 | Active not recruiting | NCT07161999 |
| Apr 2027 | Epygenix | Clemizole HClA Study of EPX-100 (Clemizole Hydrochloride) in Participants With Dravet Syndrome | Dravet Syndrome | Phase 3 | Recruiting | NCT04462770 |
| Apr 2027 | Harmony Biosciences Management, Inc. | Pitolisant tabletA Study of Pitolisant in Patients With Prader-Willi Syndrome | Prader-Willi Syndrome | Phase 3 | Recruiting | NCT06366464 |
| Apr 2027 | Jiangsu Genscend Biopharmaceutical Co., Ltd | GS101 injection, DUPIXENT®A Phase III Study of GS101 Injection to Dupixent® | Atopic Dermatitis (AD) | Phase 3 | Recruiting | NCT07386743 |
| Apr 2027 | Kodiak Sciences Inc. | KSI-101, Sham ComparatorA Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-101 in Participants With Macular Edema Secondary to Inflammation (ME… | Macular Edema Secondary to Inflammation | Phase 3 | Recruiting | NCT06990399 |
| Apr 2027 | LeonaBio, Inc. | Lasofoxifene in combination with abemaciclib, Fulvestrant in combination with abemaciclibEvaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic E… | Metastatic Breast Cancer | Phase 3 | Recruiting | NCT05696626 |
| Apr 2027 | Medicinova Inc | MN-166Evaluation of MN-166 (Ibudilast) for 12 Months Followed by an Open-label Extension for 6 Months in Patients With ALS | Amyotrophic Lateral Sclerosis | Phase 2/3 | Active not recruiting | NCT04057898 |
| Apr 2027 | RHEACELL GmbH & Co. KG | allo-APZ2-CVUAllogeneic ABCB5-positive Dermal Mesenchymal Stromal Cells for Treatment of Therapy-resistant CVU (Phase III) | Venous Leg Ulcer | Phase 3 | Active not recruiting | NCT06489028 |
| Apr 2027 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | SKB264, Paclitaxel, Nab-paclitaxel and 3 moreA Study of SKB264 Versus Investigator's Choice Chemotherapy in Patients With Unresectable Recurrent or Metastatic Triple-Negative Breast Can… | Triple Negative Breast Cancer | Phase 3 | Active not recruiting | NCT06279364 |
| Apr 2027 | Sinovac Biotech | experimental vaccine, Active Comparator vaccinePhase Ⅲ Trial of Group ACYW135 Meningococcal Conjugate Vaccine in Children Aged 6-11 Months | Epidemic Meningitis, Meningococcal Vaccines | Phase 3 | Recruiting | NCT07505823 |
| Apr 2027 | Sinovac Biotech | experimental vaccine, Active Comparator vaccinePhase Ⅲ Trial of Group ACYW135 Meningococcal Conjugate Vaccine in Children Aged 3-5 Months | Epidemic Meningitis, Meningococcal Vaccines | Phase 3 | Recruiting | NCT07505810 |
| Apr 2027 | Taiho Oncology, Inc. | futibatinib, futibatinib, fulvestrantFutibatinib in Patients Previously Enrolled in an Antecedent Futibatinib as Monotherapy or Combination Therapy. | Advanced/Metastatic Cancer | Phase 2/3 | Active not recruiting | NCT06506955 |
| Apr 2027 | Xenon Pharmaceuticals | XEN1101A Study to Evaluate XEN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic Seizures | Primary Generalized Tonic-Clonic Seizures | Phase 3 | Recruiting | NCT05667142 |
| Apr 2027 | mAbxience Research S.L. | MB11 (Proposed Nivolumab Biosimilar), EU-Opdivo®, US- sourced Opdivo®Study to Compare Pharmacokinetics, Efficacy, Safety, and Immunogenicity of MB11 Versus EU-/US-Opdivo® in Subjects With Previously Untreated … | Advanced (Unresectable or Metastatic) Melanoma | Phase 3 | Recruiting | NCT07221734 |
| Apr 2027 | vTv Therapeutics Inc. | Cadisegliatin 800 mg QD, Cadisegliatin 800 mg BIDCadisegliatin as Adjunctive Therapy to Insulin in Participants With Type 1 Diabetes | Diabetes Mellitus, Type 1 | Phase 3 | Active not recruiting | NCT06334133 |
| Apr 1, 2027 | Cerium Pharmaceuticals, Inc. | SNP-ACTH (1-39) Gel, RituximabA Study of SNP-ACTH (1-39) Gel in Patients With Primary Membranous Nephropathy | Primary Membranous Nephropathy | Phase 3 | Recruiting | NCT05696613 |
| Apr 1, 2027 | Jiangsu Famous Medical Technology Co., Ltd. | XLJDOD compound granuleXian-Lian-Jie-Du Optimization Decoction As an Adjuvant Treatment for Prevention of Recurrence of Colon Cancer | Colon Cancer | Phase 3 | Recruiting | NCT05709249 |
| Apr 1, 2027 | Jiankuan (Suzhou) Biotechnology Company Limited | ProximodA Study to Evaluate the Efficacy and Safety of Proximod in Patients With Rheumatoid Arthritis | Rheumatoid Arthrits | Phase 3 | Not yet recruiting | NCT07856511 |
| Apr 1, 2027 | Kaneka Americas Holding Inc. | Lactobacillus gasseri KABP®064 10e9 CFU/capsuleStudy to Evaluate Efficacy and Safety of Gyntima® Balance in Preventing Recurrences of Bacterial Vaginosis | Vaginosis, Bacterial, Bacterial Vaginosis and 1 more | Phase 2/3 | Not yet recruiting | NCT07527572 |
| Apr 1, 2027 | Shenzhen Sciencare Medical Industries Co., Ltd. | NaltrexoneEvaluate the Efficacy and Safety of Naltrexone Hydrochloride Implant in Patients With Alcohol Use Disorder | Alcohol Use Disorder (AUD) | Phase 3 | Not yet recruiting | NCT07433413 |
| Apr 1, 2027 | Taejoon Pharmaceutical Co., Ltd. | CTO0308Evaluate the Efficacy and Safety of CTO0308 in Pediatric Patients With Myopia | Myopia | Phase 3 | Active not recruiting | NCT07790640 |
| Apr 5, 2027 | Intra-Cellular Therapies, Inc. | LumateperoneStudy of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder | Major Depressive Disorder | Phase 3 | Recruiting | NCT05850689 |
| Apr 5, 2027 | Sanofi | Isatuximab SAR650984, Bortezomib, Lenalidomide and 1 moreA Study to Investigate the Clinical Benefit of Isatuximab in Combination With Bortezomib, Lenalidomide and Dexamethasone in Adults With Newl… | Plasma Cell Myeloma | Phase 3 | Active not recruiting | NCT03319667 |
| Apr 6, 2027 | AstraZeneca | OlaparibRoll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib | Ovarian Cancer, Breast Cancer | Phase 3 | Active not recruiting | NCT04421963 |
| Apr 6, 2027 | Csl Ltd | BE1116, FFPEfficacy and Safety of 4F-PCC (4-Factor Prothrombin Complex Concentrate) in Adult Patients Undergoing Complex Cardiovascular Surgery With Ca… | Complex Cardiovascular Surgery With Cardiopulmonary Bypass | Phase 3 | Recruiting | NCT07094087 |
| Apr 6, 2027 | Vertex Pharmaceuticals | ELX/TEZ/IVA, IVAStudy to Evaluate Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) Long-term Safety and Efficacy in Subjects Without F508del | Cystic Fibrosis | Phase 3 | Active not recruiting | NCT05331183 |
| Apr 6, 2027 | Vertex Pharmaceuticals | SuzetrigineEvaluation of Efficacy and Safety of Suzetrigine (SUZ) for Pain Associated With Diabetic Peripheral Neuropathy | Diabetic Peripheral Neuropathic Pain | Phase 3 | Recruiting | NCT07231419 |
| Apr 9, 2027 | R-Pharm International, LLC | Subcutaneous (SC) injections of OKZ 64 milligrams (mg) eve…Efficacy and Safety of Olokizumab in Patients With Progressive Fibrosing Interstitial Lung Diseases | Lung Diseases, Interstitial | Phase 2/3 | Recruiting | NCT06440746 |
| Apr 9, 2027 | Shanghai Henlius Biotech | HLX17, US-sourced Keytruda®, EU-sourced Keytruda®A Study to Compare the Efficacy, Safety, Immunogenicity, and Pharmacokinetic Profile of HLX17 Vs. Keytruda® in the First-Line Treatment of A… | Non-Squamous Non-Small Cell Lung Cancer | Phase 3 | Not yet recruiting | NCT06847334 |
| Apr 10, 2027 | Bayer | Finerenone (Kerendia, BAY94-8862)A Study to Learn More About How Well the Study Treatment Finerenone Works, How Safe it is, How it Moves Into, Through, and Out of the Body, … | Chronic Kidney Disease, Proteinuria | Phase 3 | Active not recruiting | NCT05196035 |
| Apr 12, 2027 | Novartis | ianalumabPhase 3 Study to Evaluate Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 2) | Systemic Lupus Erythematosus | Phase 3 | Active not recruiting | NCT05624749 |
| Apr 14, 2027 | Takeda Pharmaceutical Company | TDVA Study of Dengue Tetravalent Vaccine (TDV) in Adults (Age 45 to 60 and >60 to 79 Years) | Dengue Fever | Phase 3 | Active not recruiting | NCT06579755 |
| Apr 15, 2027 | Boehringer Ingelheim | NerandomilastA Study to Test Whether Nerandomilast Helps People With Lung Fibrosis Related to Rheumatic Diseases | Interstitial Lung Diseases, Systemic Autoimmune Rheumatic Diseases Associated Interstitial Lung Diseases | Phase 3 | Active not recruiting | NCT06806592 |
| Apr 16, 2027 | AstraZeneca | –Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function | Heart Failure and Impaired Kidney Function | Phase 3 | Recruiting | NCT06307652 |
| Apr 16, 2027 | Boehringer Ingelheim | EmpagliflozinA Study to Find Out How EMPAgliflozin is Tolerated and if it Helps Children and Adolescents With Chronic KIDNEY Disease (EMPA-KIDNEY® Kids) | Chronic Kidney Disease | Phase 3 | Active not recruiting | NCT07107945 |
| Apr 16, 2027 | Staidson (Beijing) Biopharmaceuticals Co., Ltd | BDB-001 injection, Cyclophosphamide, Rituximab and 2 moreBDB-001 Phase III Trial in ANCA-Associated Vasculitis | ANCA Associated Vasculitis (AAV) | Phase 3 | Recruiting | NCT07168161 |
| Apr 18, 2027 | Roche Holding | Crovalimab, EculizumabA Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Crovalimab Versus Eculizumab in Participants With Paroxysmal Nocturnal Hemo… | Paroxysmal Nocturnal Hemoglobinuria | Phase 3 | Active not recruiting | NCT04432584 |
| Apr 18, 2027 | Zydus Therapeutics Inc. | Saroglitazar Magnesium 1 mgOpen-Label Extension Study of Saroglitazar Magnesium in Participants With Primary Biliary Cholangitis | Primary Biliary Cholangitis | Phase 3 | Active not recruiting | NCT06427395 |
| Apr 19, 2027 | Amgen | Ocrelizumab (US), Ocrelizumab (EU), ABP 692Comparison Between ABP 692 and Ocrevus® (Ocrelizumab) | Relapsing-remitting Multiple Sclerosis (RRMS) | Phase 3 | Active not recruiting | NCT06700343 |
| Apr 20, 2027 | AstraZeneca | Camizestrant, Tamoxifen, Anastrozole and 2 moreA Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy | Breast Cancer, Early Breast Cancer | Phase 3 | Recruiting | NCT05774951 |
| Apr 21, 2027 | BioNTech | BNT162b2A Study of COVID-19 Vaccine(s) in Children and Adults | COVID-19 Vaccines | Phase 3 | Recruiting | NCT07798648 |
| Apr 25, 2027 | Almirall, S.A. | LebrikizumabA Study of Lebrikizumab Treatment in Adults and Adolescents With Moderate-to-Severe Atopic Dermatitis | Dermatitis, Atopic, Eczema | Phase 3 | Active not recruiting | NCT06526182 |
| Apr 25, 2027 | Oramed Pharmaceuticals | ORMD-0801 8 mg, ORMD-0801 16 mgA Phase 3 Study to Evaluate the Efficacy and Safety of ORMD-0801 in Subjects With Type 2 Diabetes Mellitus. | Type 2 Diabetes Mellitus | Phase 3 | Not yet recruiting | NCT06731075 |
| Apr 27, 2027 | Amgen | Maridebart cafraglutideEfficacy and Safety of Maridebart Cafraglutide in Adult Participants in Japan Who Have Obesity Disease | Obesity Disease | Phase 3 | Active not recruiting | NCT06987695 |
| Apr 28, 2027 | Boehringer Ingelheim | NerandomilastA Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Ne… | Idiopathic Pulmonary Fibrosis, Progressive Pulmonary Fibrosis | Phase 3 | Active not recruiting | NCT06238622 |
| Apr 28, 2027 | CSPC Pharmaceutical Group | SYHX1901A Phase III Study of SYHX1901 Tablets in the Treatment of Moderate to Severe Plaque Psoriasis | Moderate to Severe Plaque Psoriasis | Phase 3 | Not yet recruiting | NCT06943950 |
| Apr 30, 2027 | Acerta Pharma | Acalabrutinib, Venetoclax, Chemoimmunotherapy and 1 moreStudy of Acalabrutinib (ACP-196) in Combination With Venetoclax (ABT-199), With and Without Obinutuzumab (GA101) Versus Chemoimmunotherapy f… | Chronic Lymphocytic Leukemia | Phase 3 | Active not recruiting | NCT03836261 |
| Apr 30, 2027 | Bio-Thera Solutions | BAT5906 injection, LucentisEfficacy Evaluation Study of BAT5906 and Lucentis® in Patients With Diabetic Macular Edema | Diabetic Macular Edema (DME) | Phase 3 | Recruiting | NCT07515079 |
| Apr 30, 2027 | BrightGene Bio-Medical Technology Co. | BGM0504, SemaglutideA Study of BGM0504 in Participants With Type 2 Diabetes in Indonesia | Type 2 Diabetes (T2DM) | Phase 3 | Active not recruiting | NCT07064486 |
| Apr 30, 2027 | Grand Theravac Life Sciences (Nanjing) Co., Ltd. | TVAV-008, PegIFNα2b, PlacebClinical Trial to Evaluate the Efficacy and Safety of TVAX-008 Injection in the Treatment of Chronic Hepatitis B | Chronic hepatitisB | Phase 3 | Not yet recruiting | NCT07282249 |
| Apr 30, 2027 | Roche Holding | Baloxavir marboxilA Study to Confirm Efficacy of a Single Dose of Baloxavir Marboxil in the Post-exposure Prophylaxis (PEP) of Influenza Virus Infection in Ch… | Influenza, Human, Respiratory Tract Infections and 1 more | Phase 3 | Not yet recruiting | NCT07827599 |
| Apr 30, 2027 | Roche Holding | Emicizumab, von Willebrand Factor (VWF) Concentrates, Factor VIII (FVIII) Concentrates and 2 moreA Study to Assess the Efficacy and Safety of Emicizumab in Participants With Type 3 Von Willebrand Disease | Von Willebrand Disease, Type 3 | Phase 3 | Recruiting | NCT06998524 |
| Apr 30, 2027 | Incyte | Ruxolitinib CreamA Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Children (6 to < 12 Years Old) With Nonsegmental Vitiligo | NonSegmental Vitiligo | Phase 3 | Recruiting | NCT06804811 |
| Apr 30, 2027 | Innovent Biologics | Febuxostat, TigulixostatTigulixostat (IBI128) vs Febuxostat in Gout | Gout | Phase 3 | Active not recruiting | NCT07414394 |
| Apr 30, 2027 | Intuitive Surgical | filricianineIS-001 Injection in Patients Undergoing Robotic-Assisted Colorectal Surgery | Ureter Injury | Phase 3 | Recruiting | NCT07346066 |
| Apr 30, 2027 | JYAMS PET Research & Development Limited | [18F]-APN-1607Evaluate the Concordance Between PET Imaging of [18F]-APN-1607 Injection and Postmortem Brain Tissue Tau Pathology in Individuals With HV an… | Alzheimer's Disease | Phase 3 | Recruiting | NCT07752784 |
| Apr 30, 2027 | Novartis | IptacopanA Phase III Study to Investigate Efficacy, Safety and Tolerability of Iptacopan Compared With Placebo in Participants Aged 18 to 85 Years Wi… | Generalized Myasthenia Gravis | Phase 3 | Active not recruiting | NCT06517758 |
| Apr 30, 2027 | Pharmacosmos A/S | Ferric DerisomaltoseMulti-center Trial of Ferric Derisomaltose in Children 0 to <18 Years of Age With Iron Deficiency Anemia | Iron Deficiency, Anaemia in Children | Phase 3 | Recruiting | NCT05179226 |
| Apr 30, 2027 | Qilu Pharmaceutical Co., Ltd. | QL0911QL0911 for the Treatment of Cancer Treatment-Induced Thrombocytopenia | Cancer Treatment-Induced Thrombocytopenia | Phase 2/3 | Recruiting | NCT06456528 |
| Apr 30, 2027 | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | Luvometinib, Chemotherapeutic Agent COG-V/C Carboplatin + Vindesine, Ca…FCN-159 Monotherapy Versus Chemotherapy by Investigator's Choice in Pediatric Low-grade Glioma Patients With BRAF Alteration | Low-grade Glioma, Pediatric Low-grade Gliomas and 1 more | Phase 3 | Not yet recruiting | NCT07004075 |
| Apr 30, 2027 | VivaVision Biotech, Inc | VVN001 Ophthalmic Solution, 5%, VVN001 Ophthalmic Solution, VehicleStudy of 5% VVN001 Ophthalmic Solution in Dry Eye Disease | Dry Eye | Phase 3 | Recruiting | NCT06360133 |
| Apr 2027 | Akeso | AK109+AK104A Study of AK109 Combined With AK104 in Patients With Advanced Solid Tumors | Advanced Solid Tumor | Phase 1/2 | Recruiting | NCT05142423 |
| Apr 2027 | Alcon | AR-14034 SR implant lower dose, AR-14034 SR implant higher dose, AR-14034 SR implant and 2 moreStudy of AR-14034 in Participants With Neovascular Age-Related Macular Degeneration (nAMD) | Neovascular Age-related Macular Degeneration (nAMD) | Phase 1/2 | Active not recruiting | NCT05769153 |
| Apr 2027 | Jiangsu Hengrui Medicine | HRS-4029The Efficacy and Safety of HRS-4029 in Acute Ischemic Stroke Patients | Acute Ischemic Stroke | Phase 2 | Not yet recruiting | NCT07739160 |
| Apr 2027 | Beijing Sungen Biomedical Technology Co., Ltd | SGC001 injectionA Research Study to Evaluate the Efficacy and Safety of SGC001 in Patients With Anterior Wall ST-Segment Elevation Myocardial Infarction | Acute Anterior ST-Segment Elevation Myocardial Infarction | Phase 2 | Recruiting | NCT07306182 |
| Apr 2027 | CSPC Pharmaceutical Group | Docetaxel for Injection (Albumin-bound), SG001, Cisplatin for injection and 2 moreA Study of Docetaxel for Injection (Albumin-bound) and SG001 in Combination With Cisplatin and Simultaneous Radiotherapy for Locally Advance… | Locally Advanced Unresectable Esophageal Squamous Carcinoma | Phase 1/2 | Not yet recruiting | NCT06136988 |
| Apr 2027 | Caliway Biopharmaceuticals Co., Ltd. | CBL-514 Injection, 0.9% Sodium ChlorideA Study to Evaluate the Efficacy, Safety, and Tolerability of CBL-514 Injection for Reducing Abdominal Subcutaneous Fat | Subcutaneous Fat | Phase 2 | Recruiting | NCT07608770 |
| Apr 2027 | Cardurion Pharmaceuticals, Inc. | CRD-4730A Phase 2 Study of CRD-4730 in CPVT | Catecholaminergic Polymorphic Ventricular Tachycardia | Phase 2 | Recruiting | NCT06658899 |
| Apr 2027 | Cerenome | Rhenium Liposome TreatmentMaximum Tolerated Dose, Safety, and Efficacy of Rhenium Nanoliposomes in Recurrent Glioma (ReSPECT) | Glioma | Phase 1/2 | Recruiting | NCT01906385 |
| Apr 2027 | Sino Biopharmaceutical Limited | TQB3201 tabletsClinical Trial to Evaluate the Tolerance of TQB3201 Tablets | Metastatic Castration-resistant Prostate Cancer | Phase 1/2 | Not yet recruiting | NCT07172126 |
| Apr 2027 | Citryll BV | CIT-013 high dose, CIT-013 medium doseA Study With CIT-013 in HS Patients | Hidradenitis Suppurativa (HS) | Phase 2 | Active not recruiting | NCT06993233 |
| Apr 2027 | CuraCell TX AB | CC-38, Pembrolizumab, Cyclophosphamid and 2 moreA FIH, Phase I/IIa, Trial Assessing Feasibility of Administrations of TIL-based Immunotherapy in Patients With Metastatic CRC and PC | Metastatic Colorectal Cancer, Prostate Cancer Metastatic and 1 more | Phase 1/2 | Recruiting | NCT07255664 |
| Apr 2027 | D3 Bio (Wuxi) Co., Ltd | D3S-001, Pembrolizumab, Cisplatin and 3 moreA Study of D3S-001 Monotherapy or Combination Therapy in Subjects With Advanced Solid Tumors With a KRAS p.G12C Mutation | KRAS P.G12C | Phase 1/2 | Recruiting | NCT05410145 |
| Apr 2027 | Eli Lilly and Company | LY3016859 ISA, LY3556050 ISA, LY3526318 ISA and 2 moreA Master Protocol Study (LY900028) of Multiple Intervention-Specific-Appendices (ISAs) in Participants With Chronic Pain | Osteoarthritis, Knee, Diabetic Neuropathic Pain and 1 more | Phase 2 | Recruiting | NCT05986292 |
| Apr 2027 | Eli Lilly and Company | LY3537982, Pembrolizumab, Cetuximab and 3 moreStudy of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C) | Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms and 4 more | Phase 1/2 | Active not recruiting | NCT04956640 |
| Apr 2027 | Eli Lilly and Company | LY4065967A Chronic Pain Master Protocol (CPMP): A Study of LY4065967 in Participants With Chronic Low Back Pain | Chronic Pain, Low Back Pain | Phase 2 | Recruiting | NCT07641504 |
| Apr 2027 | Eli Lilly and Company | LY4065967A Chronic Pain Master Protocol (CPMP): A Study of LY4065967 in Participants With Osteoarthritis Pain | Osteoarthritis, Knee, Chronic Pain | Phase 2 | Recruiting | NCT07641517 |
| Apr 2027 | Fujian Shengdi Pharmaceutical Co., Ltd. | HRS-4729 Injection, MazdutideA Study of HRS-4729 Injection in Participants With Type 2 Diabetes | Type 2 Diabetes | Phase 2 | Not yet recruiting | NCT07843862 |
| Apr 2027 | Fujian Shengdi Pharmaceutical Co., Ltd. | HRS-5632 InjectionA Study of HRS-5632 in Adult Participants With Elevated Lipoprotein(a) at High Risk for Cardiovascular Events | Lipoprotein Disorder | Phase 2 | Active not recruiting | NCT07185776 |
| Apr 2027 | GeneCradle Inc | GC310Phase I/II Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of GC310 Injection in Patients With Wilson's Disease (WD) | Wilson Disease | Phase 1/2 | Not yet recruiting | NCT07173933 |
| Apr 2027 | GLAUKOS Corp | GLK-221 Ophthalmic SolutionPlacebo-controlled Study to Evaluate the Safety and Efficacy of GLK-221 Ophthalmic Solution in Subjects With Keratoconus | Keratoconus | Phase 2 | Recruiting | NCT07400952 |
| Apr 2027 | Jiangsu Hengrui Medicine | SHR-2173 injectionA Study of SHR-2173 in Participants With Primary IgA Nephropathy | Primary IgA Nephropathy | Phase 2 | Recruiting | NCT07354932 |
| Apr 2027 | Incannex Healthcare Inc. | IHL-42X: 2.5 mg dronabinol + 125 mg acetazolamide, IHL-42X: 5 mg dronabinol + 125 mg acetazolamide, IHL-42X: 7.5 mg dronabinol + 125 mg acetazolamide and 6 moreDReAMzz- Dronabinol and Acetazolamide Medication for Sleep Apnea (ZZ). Dose Confirmation Crossover Study for IHL-42X in Subjects With Obstru… | Obstructive Sleep Apnea (OSA) | Phase 2 | Recruiting | NCT07635563 |
| Apr 2027 | Ionis Pharmaceuticals Inc | ION717PrProfile: A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ION717 | Prion Disease | Phase 1/2 | Active not recruiting | NCT06153966 |
| Apr 2027 | Jiangsu Hengrui Medicine | SHR2554A Phase II Study of SHR2554 in Patients With Relapsed or Refractory Follicular Lymphoma | Follicular Lymphoma | Phase 2 | Not yet recruiting | NCT06368167 |
| Apr 2027 | Karyopharm Therapeutics Inc. | Selinexor, Dexamethasone, Lenalidomide and 9 moreSelinexor and Backbone Treatments of Multiple Myeloma Patients | Multiple Myeloma | Phase 1/2 | Recruiting | NCT02343042 |
| Apr 2027 | Keymed Biosciences Co.Ltd | CM350 group1, CM350 group2, CM350 group3A Study of CM350 in Patients With Advanced Solid Tumors | Advanced Solid Tumor | Phase 1/2 | Recruiting | NCT05263960 |
| Apr 2027 | Kyowa Kirin | KK2430A Phase 1/2 Study of KK2430 in Participants With Hematologic Neoplasms | Hematologic Neoplasms | Phase 1/2 | Recruiting | NCT07629726 |
| Apr 2027 | Kyverna Therapeutics, Inc. | KYV-101, Standard lymphodepletion regimen, Anti-CD20 mABKYSA-7: A Study of Anti-CD19 CAR T-Cell Therapy, in Subjects With Refractory Primary and Secondary Progressive Multiple Sclerosis | Multiple Sclerosis, Primary Progressive, Multiple Sclerosis, Secondary Progressive and 2 more | Phase 2 | Active not recruiting | NCT06384976 |
| Apr 2027 | Mikrobiomik Healthcare Company S.L. | MBK-01Clinical Trial With MBK-01, Intestinal Microbiota Capsules, for the Treatment of Patients With Recurrent Diverticulitis | Diverticulitis, Diverticulitis of Sigmoid | Phase 2 | Recruiting | NCT06687382 |
| Apr 2027 | Minghui Pharmaceutical (Hangzhou) Ltd | MHB036CA Study of MHB036C for Advanced Solid Tumor | Advanced Solid Tumor | Phase 1/2 | Active not recruiting | NCT06373406 |
| Apr 2027 | NGM Biopharmaceuticals, Inc | NGM120 Q4W, NGM120 Q8WAn Evaluation of NGM120 in a Randomized, Double-blind, Placebo-controlled Study in Participants With Colorectal Cancer Who Have Cancer Cache… | Colorectal Cancer, CRC (Colorectal Cancer) and 1 more | Phase 2 | Recruiting | NCT07033026 |
| Apr 2027 | Nkarta, Inc. | NKX019, Fludarabine, CyclophosphamideA Phase 1/2 Study of NKX019 in Subjects With Autoimmune Disease (Ntrust-1) | Lupus Nephritis, Primary Membranous Nephropathy | Phase 1/2 | Recruiting | NCT06557265 |
| Apr 2027 | Nura Bio | NB-4746 High dose, NB-4746 Low dose, NB-4746 (Dose TBD)A Clinical Trial to Evaluate NB-4746 in Participants With Amyotrophic Lateral Sclerosis. | Amyotrophic Lateral Sclerosis (ALS) | Phase 1/2 | Recruiting | NCT07369076 |
| Apr 2027 | Paean Biotechnology Inc. | PN-101Phase 2 Trial to Evaluate the Efficacy, Safety of Allogeneic Mitochondria (PN-101) in Patients With Refractory Polymyositis or Dermatomyosit… | Polymyositis, Dermatomyositis | Phase 2 | Not yet recruiting | NCT07122648 |
| Apr 2027 | Pikavation Therapeutics, Inc. | SNV4818, Fulvestrant, PalbociclibSNV4818 in Participants With Advanced Solid Tumors | Advanced Solid Tumors | Phase 1/2 | Recruiting | NCT06736704 |
| Apr 2027 | Pulmotect, Inc. | PUL-042PUL-042 Treatment in Patients With Parainfluenza Virus (PIV), Human Metapneumovirus (hMPV) or Respiratory Syncytial Virus (RSV) | Hematologic Malignancies, Hematopoietic Stem Cell Transplant (HSCT) | Phase 2 | Recruiting | NCT06665100 |
| Apr 2027 | Qilu Pharmaceutical Co., Ltd. | QLS1410Study of QLS1410 in the Treatment of Primary Aldosteronism. | Primary Aldosteronism | Phase 2 | Not yet recruiting | NCT07550465 |
| Apr 2027 | Qilu Pharmaceutical Co., Ltd. | QLS5132; Bevacizumab, QLS5132; Platinum; Bevacizumab, QLS5132; Olaparib; Bevacizumab and 2 moreQLS5132 Combination Therapy in Advanced Solid Tumors | Gastric Cancer (GC), Non-small Cell Lung Cancer (NSCLC) and 3 more | Phase 1/2 | Not yet recruiting | NCT07453394 |
| Apr 2027 | RAPT Therapeutics, Inc., a member of the GSK plc group of companies | RPT904Phase 2b Study of RPT904 as Monotherapy in Participants With IgE-Mediated Food Allergy | Ig-E Mediated Food Allergy | Phase 2 | Recruiting | NCT07220811 |
| Apr 2027 | Riboscience, LLC. | RBS2418, STRIDE (durvalumab + tremelimumab)Evaluation of RBS2418 in Combination With Tremelimumab Plus Durvalumab in Participants With Advanced Unresectable Hepatocellular Carcinoma | Advanced Unresectable Hepatocellular Carcinoma | Phase 2 | Recruiting | NCT07175441 |
| Apr 2027 | Servier Bio-Innovation LLC | S095018, S095024, S095029 and 4 morePhase 1b/2 Platform Study of Select Immunotherapy Combinations in Participants With Advanced Non-small Cell Lung Cancer (NSCLC) | Non-small Cell Lung Cancer (NSCLC) | Phase 1/2 | Active not recruiting | NCT06162572 |
| Apr 2027 | Jiangsu Hengrui Medicine | SHR-4602A Phase II Study of SHR-4602 as Montherapy or in Combination With Other Anti-tumor Therapies in Advanced Solid Tumors | Advanced Solid Tumors | Phase 2 | Not yet recruiting | NCT06704828 |
| Apr 2027 | Sinocelltech Ltd. | SCTC21CA Clinica Study of SCTC21C in Participants With Systemic Lupus Erythematosus | Systemic Lupus Erythematosus (SLE) | Phase 1/2 | Not yet recruiting | NCT07538154 |
| Apr 2027 | Sun Pharmaceutical | GL0034 Dose Level 1, GL0034 Dose Level 2, GL0034 Dose Level 3 and 3 moreEfficacy and Safety of GL0034 in Overweight or Obese Adults With Type II Diabetes Mellitus | Type II Diabetes Mellitus | Phase 2 | Recruiting | NCT07282743 |
| Apr 2027 | Jiangsu Hengrui Medicine | SHR-9839(sc) For InjectionA IB/II Phase Clinical Study on the Safety, Tolerability, and Efficacy of SHR-9839(sc) in Combination Anti-tumor Therapy in Patients With So… | Solid Tumor | Phase 1/2 | Recruiting | NCT07229638 |
| Apr 2027 | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | ZG006Dose Escalation Study of ZG006 in Participants With Advanced Small Cell Lung Cancer or Neuroendocrine Carcinoma, Followed by Dose Expansion … | Small Cell Lung Cancer, Neuroendocrine Cancer | Phase 1/2 | Recruiting | NCT06283719 |
| Apr 2027 | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | ZG005 for Injection, Gecacitinib Hydrochloride TabletsStudy of ZG005 in Combination With Gecacitinib in Patients With Relapsed or Refractory Lymphoma | Lymphoma | Phase 1/2 | Recruiting | NCT06883526 |
| Apr 2027 | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | ZG005 for Injection, Gecacitinib Hydrochloride TabletsStudy of ZG005 Combined With Gecacitinib in Patients With Advanced Non-Small Cell Lung Cancer | Non-small Cell Lung Cancer | Phase 1/2 | Recruiting | NCT06903377 |
| Apr 2027 | Trellis Bioscience LLC | TRL1068 (calpurbatug), a human monoclonal antibody, DAIRStudy to Evaluate the Efficacy and Safety of TRL1068 for the Treatment of Prosthetic Joint Infection | Prosthetic Joint Infections of Hip, Prosthetic Joint Infections of Knee | Phase 2 | Active not recruiting | NCT06621251 |
| Apr 2027 | Verrica Pharmaceuticals Inc. | VP-102Safety and Systemic Exposure of YCANTH (VP-102) in Subjects With Common Warts (Verruca Vulgaris) (COVE-5) | Common Warts, Common Warts (Verruca Vulgaris) and 2 more | Phase 2 | Not yet recruiting | NCT07881952 |
| Apr 1, 2027 | AviadoBio Ltd | Intrathalamic AAV.PGRN administration, Intrathalamic AVB-101A Study to Evaluate the Safety and Effect of AVB-101, a Gene Therapy Product, in Subjects With a Genetic Sub-type of Frontotemporal Dementia… | Frontotemporal Dementia, FTD and 2 more | Phase 1/2 | Recruiting | NCT06064890 |
| Apr 1, 2027 | Beijing Konruns Pharmaceutical Co., Ltd. | KC1036A Study of KC1036 in Adolescents With Advanced Ewing Sarcoma | Ewing Sarcoma | Phase 2 | Recruiting | NCT06564272 |
| Apr 1, 2027 | Dexlevo | DXP01, Juvederm ULTRA 3Purpose of This Study is the Demonstration of Safety and Efficacy of the Dermal Fillers DXP01 Temporary Improvement of Moderate to Severe Na… | Dermal Fillers, Nasolabial Folds, Wrinkles | Phase 2 | Not yet recruiting | NCT06885775 |
| Apr 1, 2027 | Nova Vita Laboratory | NANOVAE - Acellular Allogenic Human Amniotic Fluid (hAF), 0.9% Sodium Chloride Injection, USPNANOVAE to Treat Knee Osteoarthritis (KOA) | Knee Osteoarthritis | Phase 1/2 | Not yet recruiting | NCT06606561 |
| Apr 1, 2027 | Parabilis Medicines, Inc. | FOG-001, mFOLFOX-6, Nivolumab and 2 moreFOG-001 in Locally Advanced or Metastatic Solid Tumors | Cancer, Colorectal Cancer and 13 more | Phase 1/2 | Recruiting | NCT05919264 |
| Apr 1, 2027 | River 2 Renal Corp. | R2R01Study of the Relaxin Agonist R2R01 in Patients at High Risk for Cardiac Surgery Associated- Acute Kidney Injury | Acute Kidney Injury | Phase 2 | Recruiting | NCT07625553 |
| Apr 1, 2027 | River 3 Renal Corp. | R3R01The Evaluation of the Drug R3R01 for the Excretion of Protein in the Urine in Patients With Diabetic Kidney Disease. | Diabetic Kidney Disease | Phase 2 | Recruiting | NCT06600412 |
| Apr 1, 2027 | Shanghai JMT-Bio Inc. | JMT601 Injection, Rituximab, Cyclosporin CapsulesA Study to Learn More About the Effects and Safety of JMT601 in Adults With Primary Membranous Nephropathy | Primary Membranous Nephropathy | Phase 2 | Not yet recruiting | NCT07029139 |
| Apr 1, 2027 | Shenzhen Salubris Pharmaceuticals | SAL0140 TabletsA Phase II Clinical Trial of Efficacy and Safety of SAL0140 at Different Doses in Patients With Primary Aldosteronism | Primary Aldosteronism | Phase 2 | Not yet recruiting | NCT07646535 |
| Apr 1, 2027 | Tiziana Life Sciences Ltd | Foralumab NasalA Phase 2a Study of Foralumab Nasal in Patients With Multiple System Atrophy (MSA) | Multiple System Atrophy | Phase 2 | Recruiting | NCT06868628 |
| Apr 6, 2027 | Eisai | Perampanel Oral Suspension, Perampanel TabletA Study to Evaluate Efficacy and Safety of Perampanel Administered as an Adjunctive Therapy in Pediatric Participants With Childhood Epileps… | Pediatric Epileptic Syndrome, Partial-onset Seizures | Phase 2 | Active not recruiting | NCT04015141 |
| Apr 6, 2027 | MediLink Therapeutics (Suzhou) Co., Ltd. | YL201, YL201 and atezolizumabA Study of YL201 in Patients With Advanced Solid Tumors | Advanced Solid Tumor | Phase 1/2 | Recruiting | NCT05434234 |
| Apr 7, 2027 | Bristol-Myers Squibb | CC-99282, Rituximab, Obinutuzumab and 2 moreA Safety and Preliminary Efficacy Study of CC-99282, Alone and in Combination With Anti-lymphoma Agents in Participants With Relapsed or Ref… | Lymphoma, Non-Hodgkin | Phase 1/2 | Active not recruiting | NCT03930953 |
| Apr 8, 2027 | Sanofi | SAR444336A Study to Investigate the Efficacy and Safety of SAR444336 in Adults With Microscopic Colitis in Clinical Remission | Microscopic Colitis | Phase 2 | Recruiting | NCT07156175 |
| Apr 13, 2027 | Amgen | InebilizumabStudy of Inebilizumab in Pediatric Subjects With Neuromyelitis Optica Spectrum Disorder | Neuromyelitis Optica Spectrum Disorder | Phase 2 | Recruiting | NCT05549258 |
| Apr 14, 2027 | Beijing Biotech | EB-DNK101 dual-targeting CAR-NK cells (MSLN + MUC1), EB-DNK102 dual-targeting CAR-NK cells (CLDN18.2 + MUC1), Lymphodepleting chemotherapy (Flu/Cy)Dual-Target CAR-NK Cells Targeting Mesothelin (MSLN) and MUC1 in Advanced Pancreatic Ductal Adenocarcinoma | Pancreatic Ductal Adenocarcinoma (PDAC), Unresectable Locally Advanced and 1 more | Phase 1/2 | Recruiting | NCT07627711 |
| Apr 14, 2027 | Beijing Biotech | EB-701/CA9-NK, FludarabineDual-target CD70/CAIX CAR-NK Cells for Advanced Clear Cell Renal Cell Carcinoma | Advanced or Metastatic Clear Cell Renal Cell Carcinoma | Phase 1/2 | Recruiting | NCT07551349 |
| Apr 14, 2027 | Beijing Biotech | Autologous dual-target CAR-T cells selected from the prede…, Fludarabine, CyclophosphamideBiomarker-Guided Dual-Target CAR-T Cells for Advanced Solid Tumors | Advanced Unresectable, Metastatic | Phase 1/2 | Recruiting | NCT07523529 |
| Apr 14, 2027 | BioMarin Pharmaceutical | BMN 351A Phase 1/2 Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BMN 351 in Participants With Duchenne Muscul… | Duchenne Muscular Dystrophy | Phase 1/2 | Active not recruiting | NCT06280209 |
| Apr 14, 2027 | Novartis | [68Ga]Ga-NeoB, [177Lu]Lu-NeoB, CapecitabineA Phase I/II, Dose Finding and Optimization Study of [177Lu]Lu-NeoB in Combination With Capecitabine in Patients With GRPR+, ER+, HER2- Meta… | Breast Cancer | Phase 1/2 | Active not recruiting | NCT06247995 |
| Apr 15, 2027 | AmacaThera Inc. | AMT-143Postsurgical Analgesia After Unilateral Bunionectomy | Bunionectomy, Bunion | Phase 2 | Recruiting | NCT07858734 |
| Apr 15, 2027 | Chongqing Peg-Bio Biopharm Co., Ltd. | FT1A Clinical Study of FT1 in Patients With Short Bowel Syndrome | Short Bowel Syndrome, SBS | Phase 2 | Recruiting | NCT07704047 |
| Apr 15, 2027 | Elevara Medicines Limited | ELV001 25 mg, ELV001 75 mg, ELV001 125 mgA Study to Assess the Safety and Efficacy of Different Doses of ELV001 to Treat Active Rheumatoid Arthritis in Patients With an Inadequate R… | Active Rheumatoid Arthritis | Phase 2 | Recruiting | NCT07409103 |
| Apr 16, 2027 | Corxel Pharmaceuticals | CX11A Study of CX11 Tablets in Patients With Type 2 Diabetes Mellitus | Type II Diabetes Mellitus | Phase 2 | Recruiting | NCT07340320 |
| Apr 17, 2027 | Roche Holding | AfimkibartA Study to Assess the Efficacy and Safety of RO7790121 in Participants With Moderate to Severe Rheumatoid Arthritis Who Have Not Responded t… | Rheumatoid Arthritis | Phase 2 | Recruiting | NCT07137598 |
| Apr 20, 2027 | AstraZeneca | AZD5148Prevention of Recurrent C. Difficile Infection Study With AZD5148 Monoclonal Antibody | Clostridioides Difficile Infection | Phase 2 | Recruiting | NCT07285213 |
| Apr 22, 2027 | GSK | BepirovirsenStudy of Bepirovirsen in Participants Living With Human Immunodeficiency Virus and Chronic Hepatitis B Virus Infection (B-Focus) | Hepatitis B | Phase 2 | Active not recruiting | NCT06497504 |
| Apr 22, 2027 | Novartis | MAS825A Phase II Trial to Evaluate the Clinical Efficacy, Safety and Tolerability of MAS825 in Pediatric and Adult Participants With Still's Disea… | Still´s Disease | Phase 2 | Recruiting | NCT07203001 |
| Apr 23, 2027 | GSK | RTS,S/AS01E vaccineA Study to Assess the Safety and Immunogenicity of a Vaccine Against Malaria in Healthy Children Aged 5-60 Months | Malaria | Phase 2 | Recruiting | NCT07036159 |
| Apr 23, 2027 | Merck & Co. | Pembrolizumab, Intismeran autogene, Enfortumab Vedotin and 1 moreA Clinical Study of Intismeran Autogene (V940) Treatment and Pembrolizumab in People With Bladder Cancer (V940-005/INTerpath-005) | Bladder Cancer | Phase 1/2 | Active not recruiting | NCT06305767 |
| Apr 25, 2027 | Pfizer | Part A: ATM-AVI Single Dose, Cohorts 1-4, Part B: Multiple-dose ATM-AVI, Cohorts 1-4A Study to Learn About the Study Medicine Aztreonam-Avibactam (ATM-AVI) in Infants and Newborns Admitted in Hospitals With Bacterial Infecti… | Gram-negative Bacterial Infection | Phase 2 | Recruiting | NCT06462235 |
| Apr 25, 2027 | SinoMab BioScience Ltd | SM17 for subcutaneous injectionA Clinical Study to Evaluate SM17 for Atopic Dermatitis | Atopic Dermatitis | Phase 2 | Recruiting | NCT07445919 |
| Apr 26, 2027 | Novartis | DII235A Study of DII235 in Adults With Elevated Lipoprotein(a) | Lipoprotein Disorder | Phase 2 | Active not recruiting | NCT07235046 |
| Apr 27, 2027 | Incyte | INCB123667A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression | Ovarian Cancer | Phase 2 | Recruiting | NCT07023627 |
| Apr 27, 2027 | Johnson & Johnson | Amivantamab IV, Fluorouracil, Leucovorin and 3 moreA Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants With Advanced or Metastatic Colorectal C… | Advanced or Metastatic Colorectal Cancer | Phase 1/2 | Recruiting | NCT05379595 |
| Apr 28, 2027 | Alnylam Pharmaceuticals | ALN-2232, TirzepatideA Study to Evaluate ALN-2232 in Participants With Obesity | Obesity | Phase 1/2 | Recruiting | NCT07463846 |
| Apr 28, 2027 | Johnson & Johnson | Capmatinib, AmivantamabA Study of Amivantamab and Capmatinib Combination Therapy in Unresectable Metastatic Non-small Cell Lung Cancer | Carcinoma, Non-Small-Cell Lung | Phase 1/2 | Active not recruiting | NCT05488314 |
| Apr 28, 2027 | Novartis | QCZ484, InclisiranA Study to Evaluate the Pharmacodynamics of a Combination of QCZ484 and Inclisiran in Participants With Hypertension and Concomitant Hyperch… | Hypercholesterolaemia | Phase 2 | Recruiting | NCT07610278 |
| Apr 28, 2027 | Sanofi | Frexalimab, InsulinFrexalimab in Preservation of Endogenous Insulin Secretion Compared to Placebo in Adults, Adolescents and Children on Top of Insulin Therapy… | Type 1 Diabetes Mellitus | Phase 2 | Active not recruiting | NCT06111586 |
| Apr 29, 2027 | Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | BelzutifanA Phase 2 Study of Belzutifan (PT2977, MK-6482) for the Treatment of Von Hippel Lindau (VHL) Disease-Associated Renal Cell Carcinoma (RCC) (… | VHL - Von Hippel-Lindau Syndrome, VHL Gene Mutation and 4 more | Phase 2 | Active not recruiting | NCT03401788 |
| Apr 29, 2027 | Sanofi | BrivekimigTreatment of Type 1 Diabetes With Anti-OX40L Bispecific With Anti-TNF Activity In a Single Nanobody® Molecule | Type 1 Diabetes Mellitus | Phase 2 | Active not recruiting | NCT06812988 |
| Apr 30, 2027 | Accent Therapeutics | ATX-295, ATX-295 and bevacizumab (or biosimilar)First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, as Monotherapy and in Combination With Anticancer Therapy in Patients With Adv… | Advanced Solid Tumors, Breast Cancer Recurrent and 5 more | Phase 1/2 | Recruiting | NCT06799065 |
| Apr 30, 2027 | Akeso | AK139A Study to Evaluate the Efficacy and Safety of AK139 in Participants With Chronic Rhinosinusitis With Nasal Polyps | Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) | Phase 2 | Not yet recruiting | NCT07755371 |
| Apr 30, 2027 | Arctic Therapeutics | NPI-001Safety, Tolerability and Biomarker-based Efficacy of NPI-001 (AT-001) in Subjects With MCI or Alzheimer's Disease (AD) | Alzheimer´s Disease | Phase 2 | Active not recruiting | NCT07741526 |
| Apr 30, 2027 | Avidity Biosciences, Inc. | AOC 1044Ph2 Open-label Study of AOC 1044 in Duchenne Muscular Dystrophy Participants With Mutations Amenable to Exon44 Skipping | DMD, Duchenne Muscular Dystrophy and 2 more | Phase 2 | Active not recruiting | NCT06244082 |
| Apr 30, 2027 | CSPC Pharmaceutical Group | SYH2085A Study of SYH2085 Tablets Compared With Placebo in Chinese Adult Patients With Uncomplicated Influenza. | Influenza | Phase 2 | Not yet recruiting | NCT07798193 |
| Apr 30, 2027 | CSPC Pharmaceutical Group | Glumetinib Tablets, Docetaxel for Injection (Albumin-bound)Safety and Efficacy of Glumetinib Combined With Docetaxel for Injection (Albumin-bound) in Patients With Advanced Gastric Cancer/Gastroesoph… | Advanced Gastric Cancer/Gastroesophageal Junction Adenocarcinoma and Other Solid Tumors | Phase 2 | Recruiting | NCT06947291 |
| Apr 30, 2027 | CSPC Pharmaceutical Group | SYH2070A Study of SYH2070 Injection in Participants With Mixed Hyperlipidemia | Mixed Hyperlipidemia | Phase 2 | Recruiting | NCT07695597 |
| Apr 30, 2027 | Daiichi Sankyo | Ifinatamab deruxtecan (I-DXd)Study of Ifinatamab Deruxtecan (DS-7300a, I-DXd) in Participants With Advanced Solid Malignant Tumors | Advanced Solid Tumor, Malignant Solid Tumor | Phase 1/2 | Active not recruiting | NCT04145622 |
| Apr 30, 2027 | Genfleet Therapeutics (Shanghai) Inc. | ArmA:GFH375, Arm B:GFH375, Arm C:GFH375GFH375 Monotherapy and Combination Therapy as First-Line Treatment for Advanced KRAS G12D-Mutant Non-Small Cell Lung Cancer | NSCLC (Advanced Non-small Cell Lung Cancer) | Phase 2 | Not yet recruiting | NCT07554859 |
| Apr 30, 2027 | IDEAYA Biosciences | Darovasertib(Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular Melanoma | Uveal Melanoma | Phase 2 | Active not recruiting | NCT05907954 |
| Apr 30, 2027 | Jiangsu ProteLight Pharmaceutical & Biotechnology Co., Ltd. | –Phase II Study to Evaluate Efficacy and Safety of AMP Peptide PL-5 in Mild Infections of Diabetic Foot Ulcers | Diabetic Foot Ulcers | Phase 2 | Active not recruiting | NCT06189638 |
| Apr 30, 2027 | LimmaTech Biologics AG | VaccineAssessing the Safety, Immune Response, and Early Efficacy of a Candida Vaccine in Women With Recurrent Vulvovaginal Candidiasis: A Randomize… | Recurrent Vulvovaginal Candidiasis | Phase 1/2 | Active not recruiting | NCT06190509 |
| Apr 30, 2027 | Mirador Therapeutics, Inc. | MT-501, MT-201A Phase 2 Study to Evaluate Therapies for Inflammatory Bowel Disease | Inflammatory Bowel Disease (IBD), Ulcerative Colitis (UC) and 1 more | Phase 2 | Recruiting | NCT07113522 |
| Apr 30, 2027 | Nippon Shinyaku | NS-089/NCNP-02Extension Study of NS-089/NCNP-02 in DMD | Duchenne Muscular Dystrophy (DMD) | Phase 2 | Active not recruiting | NCT05135663 |
| Apr 30, 2027 | Pathios Therapeutics Pty Ltd | PTT-4256An Open Label Dose Finding Study of PTT-4256 in Patients With Solid Tumours (RAISIC-1). | Advanced Solid Tumor | Phase 1/2 | Recruiting | NCT06634849 |
| Apr 30, 2027 | Rgene Corporation | BLEX 404A Phase II, EvaluateBLEX 404 Combined With Gemcitabine Monotherapy With Pancreatic Cancer | Pancreatic Cancer | Phase 2 | Not yet recruiting | NCT03301805 |
| Apr 30, 2027 | Shanghai Huicun Medical Technology Co., Ltd. | Cohort 1 (1.0 × 10⁶ cells/kg), Cohort 2 (2.0 × 10⁶ cells/kg), Cohort 3 (4.0 × 10⁶ cells/kg)HCL001 Cell Injection for Decompensated Cirrhosis: A Phase I/II Trial | Decompensated Cirrhosis | Phase 1/2 | Enrolling by invitation | NCT07488546 |
| Apr 30, 2027 | Sinew Pharma Inc. | SNP-610A Randomized, Double-Blind, Placebo Controlled Study to Assess the Efficacy and Safety of SNP-610 for the Treatment of Patients With Non-alc… | NASH - Nonalcoholic Steatohepatitis | Phase 2 | Not yet recruiting | NCT03468556 |
| Apr 30, 2027 | Sinocelltech Ltd. | SCTB41Aims to Explore the Safety, Tolerability, and Preliminary Efficacy of SCTB41 in Adult Patients with Advanced Malignant Solid Tumours. | Advanced Malignant Solid Tumours | Phase 1/2 | Recruiting | NCT06600022 |
| Apr 30, 2027 | Sumitomo Pharma | Nusivertib, Ruxolitinib, MomelotinibA Study of Oral Nuvisertib (TP-3654) in Patients With Myelofibrosis | Myelofibrosis | Phase 1/2 | Recruiting | NCT04176198 |
| Apr 30, 2027 | Transcenta Therapeutics (Hangzhou) Co., Ltd. | DenosumabStudy of TST002 Injection in Postmenopausal Women With Osteoporosis or Low Bone Mass | Postmenopausal Osteoporosis, Low Bone Mass | Phase 2 | Not yet recruiting | NCT07806331 |
| Apr 30, 2027 | Uniquity One (UNI) | Solrikitug Low Dose, Solrikitug Mid Dose, Solrikitug High DoseA Study to Investigate the Efficacy and Safety of NSI-8226 in Adults With Eosinophilic Esophagitis | Eosinophilic Esophagitis (EoE) | Phase 2 | Active not recruiting | NCT06598462 |
| Apr 30, 2027 | Vibrant Sciences Limited | VIB305 for InjectionA Clinical Study to Evaluate the Safety of VIB305 in Patients With Advanced Solid Tumors | Advanced Solid Tumors | Phase 1/2 | Recruiting | NCT07222969 |
| Apr 30, 2027 | Zhejiang Doer Biologics Co., Ltd. | DR30206, Oxaliplatin, Capecitabine and 3 moreEvaluation of the Preliminary Efficacy and Safety of DR30206 in Combination With Standard Therapy in Patients With Gastrointestinal Cancer | Gastrointestinal Cancer | Phase 1/2 | Recruiting | NCT07056777 |
| Apr 30, 2027 | Argenx SE | Efgartigimod PH20 SCA Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Chronic Inflammatory Demyel… | Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) | Phase 2 | Active not recruiting | NCT04280718 |
Trials: ClinicalTrials.gov, the U.S. National Library of Medicine’s registry, industry-sponsored studies only. Completion dates are the sponsor’s own estimates and often slip. Advisory committees: the FDA advisory committee calendar. A trial’s primary completion is when its main measurement is done; companies usually report top-line results weeks to months later, and not always. FDA decision dates (PDUFA goal dates) are not here: the FDA does not publish them, and companies announce them only in their own press releases.